Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suven Life Sciences (NSE:SUVEN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Suven Life Sciences Net Margin % Related Terms
Suven Life Sciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Suven Life Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Life Sciences Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Suven Life Sciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Life Sciences (NSE:SUVEN) has a Net Margin % of -2,999.51% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Suven Life Sciences and its competitors. According to the industry distribution chart, Suven Life Sciences ranks #944 out of 962 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is Suven Life Sciences' Net Margin % too high?
Suven Life Sciences' current Net Margin % is -2,999.51%. Based on the distribution chart, Suven Life Sciences ranks #944 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Suven Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suven Life Sciences ranks #944 out of 962 companies for Net Margin %. This places Suven Life Sciences in the lower half of its industry. The industry median Net Margin % is 5.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.37, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Suven Life Sciences and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suven Life Sciences's current Net Margin % is -2,999.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (NSE:SUVEN) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹97.45, compared to a current price of ₹307.10 — trading 215.1% above its estimated fair value. The current Net Margin % is -2,999.51%. Suven Life Sciences' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Suven Life Sciences (NSE:SUVEN), the current Net Margin % is -2,999.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suven Life Sciences (NSE:SUVEN) Overvalued in 2026?
Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued.
The current stock price of ₹307.10 is trading 215.1% above its estimated GF Value™ of ₹97.45.
GuruFocus considers Suven Life Sciences to be Significantly Overvalued.
Key valuation signals for NSE:SUVEN:
Net Margin %: -2,999.51%
GF Value™: ₹97.45 vs. price of ₹307.10 (215.1% above fair value)
No single metric tells the full story. See the NSE:SUVEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
47GF Score
Get the complete analysis for NSE:SUVEN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUVEN has been successfully added to your 
